NEAT
Location:
Global, multi-site
Investigator:
Quince Therapeutics
Purpose:
To evaluate the effects of EryDex in patients with A-T. This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of dexamethasone administered by intravenous (IV) infusion (once every 28 days) on neurological symptoms of patients with A-T.
Recruitment
Parents in the United States who would like to learn more should email neatcoordination@biotrial.com.
For more information, please visit: https://clinicaltrials.gov/study/NCT06193200